Alyeska Investment Group L.P. Purchases 29,799 Shares of Recro Pharma Inc (REPH)

Alyeska Investment Group L.P. grew its stake in Recro Pharma Inc (NASDAQ:REPH) by 3.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 906,398 shares of the specialty pharmaceutical company’s stock after acquiring an additional 29,799 shares during the quarter. Alyeska Investment Group L.P. owned about 4.74% of Recro Pharma worth $8,139,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of REPH. OxFORD Asset Management LLP increased its stake in shares of Recro Pharma by 364.3% in the 2nd quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock worth $1,430,000 after acquiring an additional 159,619 shares during the last quarter. State Street Corp acquired a new stake in shares of Recro Pharma in the 2nd quarter worth $1,047,000. Northern Trust Corp increased its stake in shares of Recro Pharma by 428.5% in the 2nd quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after acquiring an additional 144,676 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Recro Pharma by 787.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock worth $911,000 after acquiring an additional 114,960 shares during the last quarter. Finally, JT Stratford LLC acquired a new stake in shares of Recro Pharma in the 2nd quarter worth $704,000. 61.55% of the stock is owned by institutional investors and hedge funds.

Shares of Recro Pharma Inc (NASDAQ REPH) opened at $9.82 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. Recro Pharma Inc has a 52-week low of $5.81 and a 52-week high of $10.59.

A number of analysts have issued reports on the company. Zacks Investment Research downgraded Recro Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 31st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a research note on Friday, October 27th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Recro Pharma presently has an average rating of “Buy” and a consensus target price of $11.65.

In related news, major shareholder Healthcare Master Fun Broadfin sold 47,549 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $9.64, for a total transaction of $458,372.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 644,813 shares of company stock valued at $6,191,579 over the last three months. Corporate insiders own 21.60% of the company’s stock.

WARNING: “Alyeska Investment Group L.P. Purchases 29,799 Shares of Recro Pharma Inc (REPH)” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://sportsperspectives.com/2017/12/12/alyeska-investment-group-l-p-purchases-29799-shares-of-recro-pharma-inc-reph.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma Inc (NASDAQ:REPH).

Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply